Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins
- 19 May 2025
- journal article
- review article
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (10) , 671-680
Abstract
Using two diseases, Alzheimer's disease and muscular dystrophy as examples, in which many resources have been invested, trends in bioanalytical techniques for detection of peptide or protein biomarkers using mass spectrometry are reviewed using Web of Science database. Amyloid beta peptides have been used to detect Alzheimer's disease, and peptides obtained by tryptic digestion of dystrophin have been used to detect muscular dystrophy. Based on the recent interest in peripheral blood analysis, literature review was focused on biofluid analysis. Both electrospray or matrix-assisted laser desorption ionization mass spectrometry were employed for amyloid beta peptides, and high-resolution or ion mobility techniques had been introduced to enhance selectivity. Immunoprecipitation techniques were often used for pretreatment; however, emergence of combined use of different solid-phase extraction mode was observed. Regarding tryptic peptides obtained from dystrophin, there are few reported applications in biofluids, and typically electrospray ionization-selected reaction monitoring with pretreatment using solid-phase extraction were employed. Validity of blood biomarkers propelled development of bioanalytical methods by attracting research interest. The analytical methodologies was built on proven methods in the field of peptide analysis, and current interests were in techniques increasing selectivity and sensitivity, such as differential mobility spectrometry or parallel reaction monitoring.Keywords
Funding Information
- Japan Society for the Promotion of Science (20H01546)
- Secom Science and Technology Foundation
This publication has 51 references indexed in Scilit:
- Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloidAlzheimer's & Dementia, 2024
- Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathologyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2024
- Clinical utility of an antibody‐free LC‐MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 StudyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseJAMA Neurology, 2021
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tauAlzheimer's & Dementia, 2021
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer DiseaseJAMA Neurology, 2021
- Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid StatusJAMA Neurology, 2019
- Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological ChangesAnnals of Neurology, 2018
- Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42JAMA Neurology, 2014